

**PIERRE-YVES CREMIEUX, PH.D.**  
**Managing Principal**

Phone: (617) 425-8135  
Fax: (617) 425-8001  
pcremieux@analysisgroup.com

111 Huntington Avenue  
Tenth Floor  
Boston, MA 02199

Pierre Crémieux, a Managing Principal of Analysis Group, has a broad range of expertise in industrial organization, health economics and health policy, antitrust, econometrics, statistics, and labor economics. He has consulted to numerous clients in the United States and Canada and testified in bench and jury trials, arbitrations, and administrative proceedings.

Dr. Crémieux has served as an expert and supported other experts in both litigation and non-litigation matters on issues including antitrust claims, generic product entry, product liability and mass tort, e-discovery sampling procedures, 10b-5 securities claims, and general commercial claims as well as a variety of labor related matters. He has assessed the evaluation of damages on a class wide basis in some of the largest class actions matters in recent years.

His scientific research in antitrust economics, class certification, health economics, and statistics has been published in numerous peer-reviewed journals including the *George Mason Law Review*, the *American Bar Association Economics Committee Newsletter*, the *Review of Economics and Statistics*, the *Journal of Health Economics*, *Industrial and Labor Relations Review*, the *Journal of Clinical Oncology*, and the *American Journal of Managed Care*. Dr. Crémieux's research has been cited in leading media outlets including the *Wall Street Journal* and *Forbes*.

Dr. Crémieux has frequently presented at leading legal, health care, and economics seminars on topics such as antitrust, class certification, health economics and statistics in both the U.S. and Canada. He has also been invited to teach courses on economics, statistics and health care at various schools including McGill University, Boston University, and Harvard Medical School.

Prior to joining Analysis Group in 1997, Dr. Crémieux spent five years as a Professor at the University du Québec à Montréal, where he still serves as an Adjunct Professor.

**EDUCATION**

Ph.D. University of California, Berkeley  
*Areas of Specialization: Industrial Organization and Labor Economics*

M.A. Economics, University of California, Berkeley

B.A. Economics, University of Maryland, College Park

## PROFESSIONAL EXPERIENCE

August 1997-present	Analysis Group, Boston, MA
August 2000-present	Adjunct Professor, Department of Economics, University du Québec à Montréal, Canada
June 1992-August 2000	Assistant and Associated Professor, Department of Economics, University du Québec à Montréal, Canada
September 1987-June 1992	Research and Teaching Assistant, Department of Economics, University of California, Berkeley, CA
September 1989-June 1990	Lecturer, Department of Economics, San Francisco State University, CA

## SELECTED CASEWORK

- **In Re: Metoprolol Succinate End-Payor Antitrust Litigation**  
*United States District Court for the District of Delaware*  
Provided expert testimony on class certification issues.
- **Bone Care International LLC and Genzyme Corporation v. Sandoz, Inc. and Eagle Pharmaceuticals, Inc**  
*United States District Court for the District of Delaware*  
Provided expert testimony on class certification issues.
- **Schering Corporation, and MSP Singapore Company LLC., v. Mylan Pharmaceuticals Inc., and Mylan, Inc,**  
*United States District Court for the District of New Jersey*  
Filed an expert report on antitrust liability and damages.
- **Genpharm ULC, Apotex Inc. and Cobalt Pharmaceuticals Inc. v. Lundbeck Canada Inc.**  
*Canadian Federal Court of Appeal*  
Filed an expert report on the impact of generic entry prior to scheduled patent expiry.
- **Flonase Antitrust Litigation (All Actions) and Roxane Laboratories, Inc. v. SmithKline Beecham Corp. d/b/a GlaxoSmithKline**  
*United States District Court for the Eastern District of Pennsylvania*  
Provided expert testimony on liability and damages issues associated with allegations relating to delayed generic entry.
- **Ortho-Clinical Diagnostics Inc. v. Abbott Japan Co., Ltd.**  
*Japan Intellectual Property High Court, 4th Department*  
Filed an expert report on statistical analysis of experimental results in a patent invalidation dispute.
- **Ortho-McNeil Pharmaceutical, Inc. v. Watson Laboratories, Sandoz, Inc. and Lupin Pharmaceuticals, Inc. and Lupin Ltd.**  
*United States District Court for the District of New Jersey*  
Provided expert testimony in a dispute associated with generic entry of oral contraceptives.
- **In Re: TFT-LCD (Flat Panel) Antitrust Litigation**  
*United States District Court, Northern District of California, San Francisco Division*  
Supported an expert in the analysis of class certification issues related to price fixing allegations

- **Hawaii Structural Ironworkers Pension Trust Fund v. Calpine Corporation**  
*Superior Court of the State of California, County of Santa Clara*  
Filed an expert report in the analysis of class certification issues in a Section 11 securities fraud litigation.
- **John P. Charters v. John Hancock Life Insurance Co. (U.S.A.)**  
*District of Massachusetts*  
Filed an expert report on issue of class and damages in a case involving alleged excess fees in exchange for services provided to group retirement plans.
- **Advanced Micro Devices, Inc., and AMD International Sales and Service, LTD., v. Intel Corporation and Intel Kabushiki Kaisha**  
*District of Delaware*  
Supported multiple experts in the analysis of claims of anticompetitive behavior including exclusionary conduct and monopolization.
- **Pat Cason-Merenda and Jeffrey et al. v. Detroit Medical Center et al.**  
*Eastern District of Michigan, Southern District*  
Supported an expert in the analysis of class certification issues related to allegations of monopsony power.
- **Discover Financial Services, DFS Services, and Discover Bank v. Visa U.S.A., et al.**  
*United States District Court for the Southern District of New York*  
Supported multiple experts on liability, damages and industry issues associated with allegation of anticompetitive behavior.
- **American Express Travel Related Services Company, Inc. v. Visa U.S.A., Inc. et al.**  
*United States District Court for the Southern District of New York*  
Supported multiple experts on liability, damages and industry issues associated with allegation of anticompetitive behavior.
- **Louisiana Wholesale Drug Co. Inc. v. Sanofi-Aventis, Sanofi-Aventis U.S., LLC and Aventis Pharmaceuticals Inc.**  
*United States District Court for the Southern District of New York*  
Provided expert testimony on liability and damages issues associated with allegations relating to delayed generic entry.
- **In Re: Katrina Canal Breaches Consolidated Litigation**  
*United States District Court for the Western District of Texas*  
Supported an expert in the analysis of class certification issues related to alleged breach of duty with respect to damages from Hurricane Katrina.
- **In Re: Vioxx Third Party Payor Litigation**  
*Supreme Court for the State of New Jersey*  
Supported an expert in the analysis of class certification issues related to alleged adverse side effects and overpayment of the drug.
- **Class Action v. Audit Bureau of Circulation**  
*Ontario Superior Court of Justice*  
Provided expert testimony in the analysis of class certification related to alleged fraud.

- **Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation**  
*United States District Court for the Northern District of California, San Francisco Division*  
Supported an expert in conducting meta analyses of clinical trials data to assess the cardiovascular safety profile of Celebrex.
- **In Re: NUI Securities, et al.**  
*United States District Court for the District of New Jersey*  
Provided damages analysis in a 10b-5 securities fraud litigation.
- **James Rizzi v. John Szoke Graphics, Inc.**  
*Arbitration*  
Provided expert testimony on alleged breach of contract.
- **Axiom Plastics, Inc. v. E.I. DuPont Canada Company**  
*Ontario Superior Court of Justice*  
Supported an expert in the analysis of class certification issues related to alleged price-fixing.
- **In Re: Royal Ahold Class Action**  
*United States District Court for the District of Maryland*  
Supported an expert and provided assistance in the settlement discussions in a class action stemming from the grocery conglomerate's accounting restatement.
- **Conroy v. 3M Company**  
*United States District Court for Northern District of California*  
Supported an expert in the analysis of indirect purchaser class certification issues related to branded and private label adhesive products.
- **Bluegreen Corporation v. David A. Siegel and David A. Siegel v. Bluegreen Corporation** *United States District Court for the Southern District of Florida*  
Supported an expert in the analysis of the economic, financial, and corporate governance implications of the adoption, by the Board of Directors of Bluegreen Corporation, of a Shareholder Rights' Plan.
- **Bracco Diagnostics Inc. v. Amersham Health Inc., Amersham Health AS and Amersham plc.**  
*United States District Court for the District of New Jersey*  
Supported an expert in the analysis of clinical trials examining the relative efficacy of two agents.
- **Heidi Turner Namiot v. Swiss Re Financial Product Corp**  
*United States District Court for the Southern District of New York*  
Provided expert testimony on issues related to termination.
- **Ortho Biotech Products, L.P. v. Amgen Inc. and Amgen USA Inc.**  
*United States District Court for the District of New Jersey*  
Provided expert testimony on the relative cost of two leading erythropoietic agents in an antitrust case.
- **In Re: Insurance Brokerage Antitrust Litigation**  
*United States District Court for the District of New Jersey*  
Supported an expert in the analysis of class certification related to alleged anticompetitive acts in the commercial insurance industry.

- **California State Auditor’s Office**  
Drafted a report to the California State Auditor on the “cost-effectiveness and quality of health care in California State Prisons.”
- **Farmers Cooperative Elevator Co., et al. v. Akzo Nobel, Inc., et al.**  
*Iowa District Court for Carroll County*  
Supported an expert in the analysis of indirect purchaser class certification related to alleged price-fixing of vitamins products.
- **In Re: NBR Antitrust Litigation**  
*United States District Court for the Western District of Pennsylvania*  
Supported an expert in the analysis of class certification related to alleged price-fixing and market allocation of acrylonitrile butadiene rubber.
- **Paymaster Technologies v. The United States**  
*United States Court of Federal Claims*  
Provided expert testimony in an intellectual property dispute.
- **Ortho-McNeil Pharmaceutical, Inc. v. Barr Laboratories, Inc.**  
*United States District Court for the District of New Jersey*  
Provided expert testimony in a dispute associated with generic entry of oral contraceptives.
- **In Re: Microsoft I-V Cases**  
*United States Superior Court of the State of California for the City and County of San Francisco*  
Supported several experts in an analysis of potential damages resulting from alleged anticompetitive acts.
- **Kellogg Company v. BASF AG, et al.**  
*United States District Court for the District of Columbia*  
Supported an expert in an analysis of potential damages resulting from alleged anticompetitive acts.
- **United States of America v. Hoyts Cinemas Corporation and National Amusements, Inc.** *United States District Court for the District of Massachusetts*  
Provided expert testimony on alleged violation of the American with Disabilities Act..
- **Susan Douglass v. Ernst & Young, LLP**  
*United States District Court for the District of Massachusetts*  
Provided expert testimony on damages associated with allegations of illegal termination.
- **Cory Breakstone v. J.T. Magen**  
*Supreme Court of the State of New York, County of New York*  
Provided econometric analysis of earnings in the construction industry.
- **EMC Corporation v. Joanna T. Karwowska**  
*United States District Court for the District of Massachusetts*  
Provided expert testimony on allegations of breach of non compete.
- **Calvin L. Keeler v. Putnam Fiduciary Trust**  
*United States District Court for the District of Massachusetts*  
Rebutted statistical analysis of earnings and employment analysis.
- **Dr. Ben S. Branch, Trustee of Bank of New England Corporation v. Federal Deposit Insurance Corporation as Receiver of New Bank of New England, N.A., et al.**

*United States District Court for the District of Massachusetts*

Provided financial and economic analysis of the probability of bank failure using econometric and statistical analysis.

- **In Re: Brand Name Prescription Drug Litigation**  
*United States District Court for the Northern District of Illinois*  
Supported expert in the analysis of potential damages associated with allegations of anticompetitive acts.
- **Iain Fraser, et al. v. Major League Soccer L.L.C., et al.**  
*United States District Court for the District of Massachusetts*  
Supported an expert in the analysis of the potential impact of anticompetitive acts.
- **Fitzpatrick v. Medical Resources, Inc.**  
*Massachusetts Commission Against Discrimination*  
Provided statistical and econometric analysis of earnings levels and employment probability.
- **Mr. Guecia v. Roman Catholic Archbishop of Boston, A Corporation Sole**  
*United States Superior Court of the State of Massachusetts for the County of Suffolk*  
Provided expert testimony on damages resulting from allegations of abuse (Pro bono).
- **In Re: Food and Drug Administration**  
Testified before the FDA as part of a labeling change.
- **In Re: Québec Assemblée Nationale**  
Testified before a House Committee on pharmaceutical pricing.
- **In Re: Food and Drug Administration**  
Testified before the FDA as part of a labeling request.
- **In Re: Québec Assemblée Nationale**  
Testified before a house committee on tobacco legislation.
- **In Re: Canadian House of Commons**  
Testified before a House Committee on unemployment insurance.
- **In Re: Health Care Financing Administration**  
Testified before the HCFA as part of a cost benefit analysis.

## **PUBLICATIONS AND PRESENTATIONS**

### **Legal and Business**

Pierre-Yves Crémieux, George Kosicki and Tammy Sisitsky (2010) “The Role of Expert in Antitrust Class Certification,” *Antitrust Class Actions Handbook*.

Pierre-Yves Crémieux and Edward A. Snyder (2010) “Global Antitrust Enforcement: An Empirical Assessment of the Influence of Protectionism,” *Stigler Center for the Study of the Economy and the State Working paper #233*.

Pierre-Yves Crémieux, Ian Simmons and Edward A. Snyder (2010) “A New Approach to Antitrust Class Certification,” *Law 360*, June 14, 2010

Pierre-Yves Crémieux, Ian Simmons and Edward A. Snyder (2010) “Proof of Common Impact in Antitrust Litigation: The Value of Regression Analysis,” *George Mason Law Review* 17.

Pierre-Yves Crémieux, Elizabeth Eccher, and Steven Herscovici (2007) “Getting the Most Out of Your Experts,” in Expert Alert, *American Bar Association Litigation Section*.

Pierre-Yves Crémieux, Adam Decter, Steven Herscovici, and Robert Mascola (2006) “Assessing Conflict, Impact, and Common Methods of Proof in Intermediate Indirect-Purchaser Class Action Litigation,” in *American Bar Association Economics Committee Newsletter*;6(1):4-10.

Pierre-Yves Crémieux and Paul Greenberg (2004) “Product Liability in the Pharmaceutical Industry,” in *Update Magazine*.

## Health

Pierre-Yves Crémieux, Sara Eapen, Stephen Trask, Arindam Ghosh (forthcoming) “Weighing the Economic Impact and Clinical Benefits of Bariatric Surgery in Morbidly Obese Patients with Diabetes: A Review” *Canadian Journal of Diabetes*.

John Dawson, Pierre-Yves Crémieux and Arindam Ghosh (forthcoming) “Weighing the Benefits: The Economics of Obesity Surgery,” *Contingencies*.

Samuel Klein, Arindam Ghosh, Pierre Y. Crémieux, Sara Eapen and Tamara J. McGavock (2010) “Economic Impact of the Clinical Benefits of Bariatric Surgery in Diabetes Patients With BMI  $\geq 35\text{kg/m}^2$ ” *Obesity*.

Pierre-Yves Crémieux (2010) “Methodological Issues in a Meta-Analysis” Letter to the Editor, *Hepatology*; 52 (1): 395-397.

Pierre-Yves Crémieux, Severine Ledoux, Christine Clerici, Francois Crémieux, Marris Buessing (2010) “The impact of bariatric surgery on comorbidities and medication use among obese patients” *Obesity Surgery*; 20 (7): 861-870.

Howard Birnbaum, Rym Ben-Hamadi, David Kelley, Matthew Hsieh, Brian Seal, Evan Kantor, Pierre Y. Crémieux, and Paul E. Greenberg (2010) “Assessing The Relationship Between Compliance With Antidepressant Therapy And Employer Costs Among Employees In The United States,” *Journal of Occupational and Environmental Medicine*; 52(2) : 115-124.

Lu Tian, Tianxi Cai, Marc A. Pfeffer, Nikita Piankov, Pierre Crémieux and L. J. Wei (2009) “Exact and efficient inference procedure for meta-analysis and its application to the analysis of 2x2 tables with all available data but with artificial continuity correction,” in *Biostatistics*; 10: 275-281.

Daniel Bilodeau, Pierre-Yves Crémieux, and Pierre Ouellette (2009) “Hospital Performance in a Non-Competitive Environment,” in *Applied Economics*; 41(2-6) :459-468.

Howard G. Birnbaum, Jasmina I. Ivanova, Seth Samuels, Matthew Davis, Pierre Y. Crémieux, Amy L. Phillips, and Dennis Meletiche (2009) “Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs,” in *Current Medical Research and Opinion*; 25(4): 869-877.

- Pierre-Yves Crémieux, Henry Buchwald, Scott Shikora, Arindam Ghosh, Elaine Yang, and Marris Buessing (2008) "A Study on the Economic Impact of Bariatric Surgery," in *American Journal of Managed Care*; 14(9): 589-597.
- Mei Sheng Duh, Frederick Andermann, Pierre Emmanuel Paradis, Jennifer Weiner, Ranjani Manjunath, and Pierre-Yves Crémieux (2007) "The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of Lamotrigine," in *Disease Management*; 10(4): 216-25.
- Pierre-Yves Crémieux, Pierre Fortin, Marie Claude Meilleur, Terrence Montague, and Jimmy Royer (2007) "The Economic Impact of a Partnership Measurement Model of Disease Management: Improving Cardiovascular Outcomes in Nova Scotia," in *Healthcare Quarterly*; 10(2):36-44.
- Pierre-Yves Crémieux, Pierre Ouellette, and Patrick Petit (2007) "Do Drugs Reduce Utilization of Other Health Care Resources?" in *Pharmacoeconomics*; 25(3):209-21.
- David Cutler, Genia Long, Ernst Berndt, Jimmy Royer, Andrée-Anne Fournier, Alicia Sasser, and Pierre-Yves Crémieux (2007) "The Value of Antihypertensive Drugs: A Perspective on Medical Innovation," in *Health Affairs*; 26(1):97-110.
- Pierre-Yves Crémieux, Denise Jarvinen, Philip Merrigan, and Genia Long (2007) "Pharmaceutical Spending and Health Outcomes," in *Pharmaceutical Innovation: Incentives, Competition and Cost-Benefit Analysis in International Perspective* Frank A. Sloan and Chee-Ruey Hsieh (Ed.), Cambridge University Press, New York.
- Patrick Lefebvre, Francis Vekeman, Brenda Sarokhan, Christopher Enny, Robert Provenzano, and Pierre-Yves Crémieux (2006) "Relationship Between Hemoglobin Level and Quality of Life in Anemic Patients with Chronic Kidney Disease Receiving Epoetin Alfa," in *Current Medical Research and Opinions*; 22:1929-37.
- Pierre-Yves Crémieux, Dominique Latremouille-Viau, Philip Merrigan and Pierre Ouellette (2006) Les tendances dans la consommation de médicaments au Canada de 1994 à 2002 : Une analyse descriptive » in *Le Point en administration de la santé et des services sociaux*, 2(2) : 24-29.
- Pierre-Yves Crémieux, Marc Van Audenrode, and Patrick Lefebvre (2006) "The Relative Dosing of Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease," in *Current Medical Research and Opinion*; 22(12):2329-36.
- Pierre-Yves Crémieux, Francis Vekeman, and Patrick Lefebvre (2006) "Dose Conversion and Cost Effectiveness of Erythropoietic Therapies in Chemotherapy-related Anemia: A Canadian Application," in *Journal of Oncology Pharmacy Practice*; 12:1-14.
- Pierre-Yves Crémieux (2005) "L'impact des dépenses en médicaments sur les coûts de santé et l'état de santé des populations," in *Les Cahiers du Geirso*; 1(4):88-102.
- James Rosberg, Rym Ben-Hamadi, Pierre-Yves Crémieux, John Fastenau, Catherine Piech (2005) "Dose Conversion and Cost-Effectiveness of Erythropoietic Therapies in Chemotherapy-related Anemia: A Meta-Analysis," in *Clinical Drug Investigation*; 25(1):33-48.
- Pierre-Yves Crémieux, Pierre Ouellette, François Rimbaud, and Stéphane Vigeant (2005) "Hospital Cost Flexibility in the Presence of Many Outputs: A Public-Private Comparison," in *Health Care Management Science*; 8:111-22.

Daniel Shasha, Pierre-Yves Crémieux, and Louis Harrison (2004) "Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients with Cancer and Anemia Treated with Epoetin Alfa," in *Journal of the National Comprehensive Cancer Network*;2(5):509-17.

Pierre-Yves Crémieux, John Fastenau, George Kosicki, Catherine Piech, and A. Mark Fendrick (2004) "Cost-Minimization Analysis of Once-Weekly vs. Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia," in *Journal of Managed Care Pharmacy*;531-37.

Andrine Swensen, Howard Birnbaum, Rym Ben-Hamadi, Paul Greenberg, Pierre-Yves Crémieux, and Kristina Secnik (2004) "Incidence and Costs of Accidents Among Attention-Deficit/Hyperactive Disorder Patients," in *Journal of Adolescent Health*;35(4):346-47.

Pierre-Yves Crémieux, Marie-Claude Meilleur, Pierre Ouellette, Patrick Petit, Martin Zelder, and Ken Potvin (2004) "Public and Private Pharmaceutical Spending as Determinants of Health Outcomes in Canada," in *Health Economics*;14:107-16.

Daniel Bilodeau, Pierre-Yves Crémieux, Brigitte Jaumard, Pierre Ouellette, and Tsévi Vovor (2004) "Measuring Hospital Efficiency in the Presence of Quasi-Fixed Inputs: An Analysis of Québec Hospitals," in *Journal of Productivity Analysis*;21(2):183-99.

Pierre-Yves Crémieux, Ellison Dial, Mark Gustafson, Brenda Sarokhan, and Mitchell Slavin (2002) "Cost Effectiveness of rHuEPO in Oncology," in *Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer*, M.R. Nowrousian (Ed.), SpringerWien New York, 2002.

Daniel Bilodeau, Pierre-Yves Crémieux, and Pierre Ouellette (2002) "Hospital Technology in a Non-Market Health Care System," in *Southern Economic Journal*;68(3):511-29.

Jeffrey Crawford, David Cella, Charles Cleeland, Pierre-Yves Crémieux, George Demetri, Brenda Sarokhan, Mitchell Slavin, and John Glaspy (2002) "Relationship Between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy," in *Cancer*;95(4):888-95.

Janice Gabrilove, Brenda Sarokhan, and Pierre-Yves Crémieux (2002) "Statistical Explanations for a Community-Based Study of Once-Weekly Epoetin Alfa Therapy in Patients Receiving Chemotherapy," in *Journal of Clinical Oncology*;20(11):2757-58.

Pierre Crémieux, Mitchell Slavin, A. Mark Fendrick, Tom Hiriak, and George Kosicki (2001) "The costs of cancer: cancer-related conditions can add dramatically to overall costs of care," in *Journal of Managed Care Medicine*;5(12):8-12.

Arnold Barnett, Pierre-Yves Crémieux, A. Mark Fendrick, Martine George, and Mitchell Slavin (2001) "Anemia-Related Costs for Cancer Patients," in *Journal of Managed Care Medicine*;5(12):14-16.

Jean-Pierre Bluteau, Pierre-Yves Crémieux, and Pierre Ouellette (2001) "L'évolution du régime d'assurance-médicament," (Changes in the Drug Prescription Coverage in Quebec) in *Annuaire du Québec*;Editions Fides.

Pierre-Yves Crémieux, Pierre Ouellette, Marie-Claude Meilleur, Stephanie Leong, Paul Greenberg, and Howard Birnbaum (2001) "Pharmaceutical Spending and Health Outcomes in the United States," in *Investing in Health: The Social and Economic Benefits of Health Care Innovation*, I. Farquar, K. Summers, and A. Sorkin, Editors. Elsevier Science, New York, NY.

Pierre-Yves Crémieux, Denis Gadbois, Brigitte Jaumard, Pierre Ouellette, and Tsévi Vovor (2001) L'évaluation de l'efficacité budgétaire des CLSC au Québec à partir de la méthode DEA," (An Evaluation of the Budgetary Efficiency of Local Community Clinics in Quebec Based on a DEA Approach) in *L'Actualité Economique*;77(3):409-24.

Pierre Crémieux and Pierre Ouellette (2001) "Omitted Variable Bias and Hospital Costs," in *Journal of Health Economics*;20(2):271-83.

Pierre-Yves Crémieux and Pierre Ouellette (2001) "Actual and Perceived Impacts of Tobacco Regulation on Restaurants and Firms," in *Tobacco Control*;10:33-7.

Howard Birnbaum, Pierre Crémieux, and Paul Greenberg (2000) "Understanding the Pharmacoeconomic Profile of Cancer," in *ONE: Oncology Economics*;1(10):36-9.

Pierre-Yves Crémieux, Jacques Leloir, and Pierre Ouellette (2000) "Dépenses de santé, indicateurs de santé et impact de nouvelles pharmacothérapies," ("Health Care Expenditures, Outcome Measures and new Pharmacotherapies") Report to the Commission of Social Affairs, Quebec National Assembly, February 15, 2000.\

Pierre-Yves Crémieux and Pierre Ouellette (2000) "Diagnosing the Illness," in *Policy Options*;12(4):12-4.

Pierre Crémieux, Matthew Gubens, Michael Holland, and Mitchell Slavin (2000) "Costs Associated with Anemia and Cancer," in *ONE: Oncology Economics*;1(11):1-7.

Howard Birnbaum, Pierre Crémieux, Paul Greenberg, and Ronald Kessler (2000) "Management of Major Depression in the Workplace: Impact on Employee Work Loss," in *Disease Management & Health Outcomes*;7(3):163-71.

Pierre-Yves Crémieux, Barbara Barrett, Kenneth Anderson, and Mitchell Slavin (2000) "Cost of Outpatient Blood Transfusion in Cancer Patients," in *Journal of Clinical Oncology*;18(14):2755-61.

Arnold Barnett, Howard Birnbaum, Pierre-Yves Crémieux, A. Mark Fendrick, and Mitchell Slavin (2000) "The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis," in *American Journal of Managed Care*;6(11):1243-51.

Daniel Bilodeau, Pierre-Yves Crémieux, and Pierre Ouellette (2000) "Hospital Cost Function in a Non-Market Health Care System," in *Review of Economics and Statistics*;82(3):1-11.

Howard Birnbaum, Pierre-Yves Crémieux, Paul Greenberg, Jacques LeLorier, JoAnn Ostrander, and Laura Venditti (1999) "Using Health Care Claims Data for Outcomes Research and Pharmacoeconomic Analyses," in *Pharmacoeconomics*;16(1):1-8.

Pierre-Yves Crémieux, Pierre Ouellette, and Caroline Pilon (1999) "Public and Private Health Care Spending as Determinants of Health Outcomes," in *Health Economics*;8:627-39.

Pierre-Yves Crémieux, Stan Finkelstein, Ernst Berndt, Jeffrey Crawford, and Mitchell Slavin (1999) "Cost-Effectiveness, Quality-Adjusted Life Years, and Supportive Care: Recombinant Human Erythropoietin as Treatment of Cancer-Associated Anemia," in *Pharmacoeconomics*;16(5):459-72.

Paul Greenberg, Mary Barton, Howard Birnbaum, Pierre-Yves Crémieux, Mitchell Slavin, Fabian D'Souza, and Becky Auerbach (1999) "Tackling Costs One Disease at a Time," in *Business and Health*;5:31-7.

Paul Greenberg, Almudena Arcelus, Howard Birnbaum, Pierre-Yves Crémieux, Jacques Leloirier, Pierre Ouellette, and Mitchell Slavin (1999) "Pharmacoeconomics and Health Policy: Current Applications and Prospects for the Future," in *Pharmacoeconomics*;16(5):1-8.

Pierre-Yves Crémieux, Pierre Ouellette, and Denis Gadbois (1998) "La performance des CLSC au Québec," (Local Health Clinic Performance in Québec) in *l'Actualité Economique*;74(2):157-81.

Pierre-Yves Crémieux, Pierre Fortin, Frederic Lavoie, Pierre Ouellette, and Yvan St. Pierre (1997) "Etude d'Impact du Projet de Loi sur le Tabac," (Impact Report on the Proposed Tobacco Law) in *Ministry of Health and Social Services*.

Pierre-Yves Crémieux and Pierre Ouellette (1997) "Une analyse du contexte budgétaire de l'activité médicale au Québec," (An Analysis of the Budgetary Context of Medical Activity in Québec) in *Le Médecin du Québec*.

## Labor

Pierre Crémieux (forthcoming). Review of the Book Monopsony in Law and Economics by Roger D. Blair and Jeffrey L. Harrison, *Journal of Economic Literature*.

Pierre Crémieux, Paul Greenberg, Ronald Kessler, Philip Merrigan, and Marc Van Audenrode (2004) "Employment, Earnings Supplements, and Mental Health: A Controlled Experiment," Social Research and Demonstration Corporation, Working Paper #04-01.

Pierre-Yves Crémieux (1998) "Le marché du travail et l'évolution des salaires dans le transport aérien aux Etats-Unis: L'effet de la déréglementation de 1978," (Labor Market and Wage Patterns in U.S. Air Transport: The Effect of the 1978 Deregulation) in *Economie et Prévision*.

Pierre-Yves Crémieux (1996) "Why Strike Insurance is Unilateral: Evidence From the Airline Industry's Mutual Aid Pact," in *Journal of Labor Research*;17(2).

Pierre-Yves Crémieux (1996) "The Effect of Deregulation on Employee Earnings: Pilots, Flight Attendants, and Mechanics: 1959-1992," in *Industrial and Labor and Relations Review*;49(2):223-42.

Pierre-Yves Crémieux and Marc Van Audenrode (1996) "Mergers and Bargaining in the U.S. Airline Industry," in *Review of Labour Economics and Industrial Relations*;10(2).

Pierre-Yves Crémieux and Marc Van Audenrode (1996) "Is the U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis," in *The Flow Approach to Labor Market Analysis*, Ronald Shettkat, editor. Rutledge: New York.

Pierre-Yves Crémieux, Pierre Fortin, Paul Storer, and Marc Van Audenrode (1995) "Unemployment Insurance and Job Search Productivity," in *Insurance Program Evaluation Report, Human Resources Development Canada*.

Pierre-Yves Crémieux, Pierre Fortin, Paul Storer, and Marc Van Audenrode (1995) "The Impact of Unemployment Insurance on Job-Search Productivity, the Reservation Wage, the Probability of Re-Employment, and the Post-Displacement Wage," in *Insurance Program Evaluation Report, Human Resources Development Canada*.

Pierre-Yves Crémieux, Pierre Fortin, and Marc Van Audenrode (1994) “L’*évolution macroéconomique et la question budgétaire au Québec*,” (Macroeconomic Evolution and the Budgetary Question in Québec) in *Health and Welfare Council*.

### **Policy, Civic, and Social Issues Publications**

“The Cost-Effectiveness and Quality of Health Care in California’s State Prisons.” Co-authored report to the California State Auditor’s Office (January 2000).

“The Privatization Process of the Publicly Owned Companies in Haïti: Observations and Recommendations,” (in French with André Marcoux). Report of the observation mission of “Concertation Pour Haïti” on the privatization of publicly owned companies (November 1996).

“The Economic and Social Impact of the Community Service in Four Districts of the City of Montréal,” (joint work in French). Service aux collectivités de l’UQAM (October 1996).

“A Profile of the Work Force in the Rosemont Petite-Patrie District,” Report to the CDEC Rosemont Petite-Patrie within the framework of the ANGUS development project (in French, October 1995).

“For a Contribution of the FTQ to the Development and Promotion of Tourism in Quebec,” (Decembre 1994). Feasibility study (joint work in French).

“Une analyse quantitative de la position des québécois face à l’aide sociale,” (A Quantitative Analysis of Quebecer’s Position Towards Welfare). Report to the Commission on Welfare Reform (January 1995).

“Question de niveau,” *La Presse* December 10, 1993.

“The Last Federal Budget and the Unemployed: Surprising and Disturbing Issues,” *La Presse* (in French) and *Ottawa Citizen* (in English), March 9, 1994, with Pierre Fortin and Marc Van Audenrode.

“Rise in the Minimum Wage: Little Risk for Employment and Competitiveness,” *La Presse* (in French), June 2, 1995.

“The Level of the Minimum Wage,” *Le Devoir* (in French), May 15, 1996.

### **Selected Presentations**

“Proving Common Impact in Antitrust Class Certification,” seminar presented at the University of Chicago Gleacher Center, Chicago, IL, May 12, 2010.

“The Cost Effectiveness of Surgery for Type 2 Diabetes Mellitus,” presented at the First Canadian Summit on Surgery for T2DM, Montreal, Canada, May 2010

“Global Antitrust Enforcement, an Empirical Assessment of Protectionism,” presented at the Boston Bar Association, March 2010.

“A period of increased risk for competition policy,” presented at the Centro de Estudios Publicos, Santiago, Chile, September 2009.

“The Economic Impact of Bariatric Surgery, an ROI Analysis,” presented to the National Business Group on Health, Institute on the Costs and Health Effects of Obesity, February 2009

“A Study on the Economic Impact of Bariatric Surgery,” presented at the 94th Annual Clinical Congress of the American College of Surgeons, October 2008.

“Economics and Cost Effectiveness of Surgery for Diabetes,” presented at the 1st World Congress on Interventional Therapies for Type 2 Diabetes, September 2008.

“Developments in Class Certification in the U.S. and Abroad,” presented at an ABA Teleconference, June 2008.

“The Prevalence of Pediatric Mental Illness and Treatment in the United States,” presented at the 2nd International Conference on the Pharmaceutical Life Cycle, October 2007.

“Biostatistics and Pharmacoeconomics: Introduction to Statistical Methods and Applications to Medical Scientific Literature,” presented at various medical schools, universities, and hospitals, 2006-2007.

“Can We Put a Price on the Value of Medicine?” presented at the Summit on the Value of Medicine, February 2007.

“Biostatistics and Pharmacoeconomics: Introduction to Statistical Methods in the Medical Literature,” presented at GEIRSO, October 2006.

“Evaluating the Cost-Benefit of Bariatric Surgery and Laparoscopic Band,” presented at the World Congress Conference on Implementation and Cost Benefit of Workplace Weight Management Strategies, June 2006.

“The Impact of Bariatric Surgery on Health Outcomes and Pharmacological Treatment Among Obese Patients in an Employed Population,” presented at the International Society for Pharmacoeconomics and Outcomes Research, May 2006.

“Using Economic Experts in the Battle for Predominance,” presented at Law Seminars International, February 2006.

“Litigating Mass Tort in Canada: The Nexus of Epidemiology, Economics, and Law,” presented at Insight Conference on Drug Safety, January 2006.

“L’utilisation d’approches épidémiologiques et statistiques pour la défense des recours collectifs concernant les produits défectueux,” (The Use of Epidemiology and Statistics to Defend Class Actions in Mass Tort Cases) presented at Conférence Insight sur le système de santé au Québec, Janvier, 2006.

“L’impact des dépenses en médicaments sur les coûts de santé et l’état de santé des populations,” (The Impact of Pharmaceutical Spending on Health Care Costs and Population Health Outcomes) presented at Institut Canadien de la retraite et des avantages sociaux, September 2004.

“Impact des dépenses en soins de santé et médicaments sur la santé de la population : une analyse provinciale,” (The Impact of Health Care and Pharmaceutical Spending on Health Outcomes: A Provincial Analysis) presented at Société Canadienne des sciences économiques, Mai 2004.

“Providing Economic Analysis in the Context of Antitrust Litigation,” presented at Brandeis University, October 2003.

“A Health Economics Perspective on Quality-of-Life Versus Life-preserving Therapies,” presented at Business and Health Consensus Panel, June 2000.

“Health Economics and Pharmacoeconomic Analysis,” presented at Harvard Medical School, February 2000.

“Economic Trends in the Health Care System,” presented at Association Québécoise des Pharmaciens Propriétaires, December 1999.

“A DEA Application to Hospital Performance Analysis in a Non-Competitive Environment,” presented at Canadian Economic Association, June 1999.

“The Cost-Effectiveness of r-HuEPO in Cancer Patients with Chemotherapy-Related Anemia,” presented at Edmonton University Hospital, May 1999.

“The Cost-Effectiveness of r-HuEPO in Cancer Patients with Chemotherapy-Related Anemia,” presented at Winnipeg University Hospital, May 1999.

“Pharmacoeconomics and Cost Effectiveness,” presented at Harvard Medical School, February 1998.

“The Economics Most Worth Knowing,” lecture to the sales force of a major pharmaceutical company, January 1998.

“Acute Care Hospitals in Québec: A Performance Analysis Based on Panel Data,” 6<sup>ème</sup> journées d'étude des données de Panel, June 1996.

“Is the U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis,” presented at Canadian Economics Association, June 1995.

“The Effect of Deregulation on Employee Earnings: Pilots, Flight Attendants, and Mechanics: 1959-1992,” 5<sup>ème</sup> journées d'étude des données de panel, June 1994.

“L'Évolution macroéconomique et la question Budgétaire au Québec,” (The Macroeconomic Context and Budgetary Issues in Quebec) presented at Health and Welfare Council, November 1994.

“Is the U.S./Canada Unemployment Gap Truly Large? A Labor Flow Analysis,” presented at Conference on Labor Flows, December 1994.

“Rent Sharing in the Airline Industry: Evidence from Mergers and Acquisitions,” presented at Société Canadienne des Sciences Economiques, May 1993.

“Rent Sharing in the Airline Industry: Evidence from Mergers and Acquisitions,” presented at University of California at Berkeley, June 1993.

“The Effect of Strike Insurance on Labor Earnings,” presented at Université of Montréal, UQAM, University Laval, January 1992.

## **ACADEMIC RESEARCH GRANTS**

Principal Investigator: Pierre Ouellette, Université du Québec à Montréal

Funding source: Quebec Ministry of Health (1997)

Title: “Etude d'impact sur le projet de loi sur le tabac” (Analysis of the impact of a proposed legislation on tobacco)

Amount: \$75,000

Principal Investigator: Pierre Crémieux, Pierre Ouellette, and Pierre Fortin, Université du Québec à Montréal

Funding source: Quebec Ministry of Research, FCAR (2001-2004)

Title: “Performance hospitalière” (Hospital performance)

Amount: \$75,000

Principal Investigator: Catherine Garnier, Université du Québec à Montréal

Funding source: Canadian government (2003-2008)

Title: “La chaîne du médicament” (The drug process)

Amount: \$2,500,000

**OTHER**

Drug Safety and Monitoring Board, Genta Inc.

Labor Economics, Ph.D. course, Boston University, Spring 2007, Spring 2009.

External committee member, Ph.D. Thesis, Madame Michele Savoie, Une étude de Propension à payer pour la prévention du cancer du sein, Département des sciences biomédicales, Faculté de Médecine. Jacques Le Lorier and Pierre Ouellette, Co-advisors.

Evaluation of the Masters Programs of the Centre des Techniques de Planification et d'Economie Appliquée in Haiti (1996).

Member of the Observation Mission for the *Concertation pour Haiti* on the privatization of state owned companies in Haiti (1997).

President, Medical Aid Committee.